2017 annual financial data

CRISPR Therapeutics 2017 Financial results

Direct answer

Revenue was 40,997,000 USD.

Operating income was -64,648,000 USD and net income was -68,357,000 USD.
Operating cash flow was -70,097,000 USD.

Get free CRISPR Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
40,997,000 USD
Operating income
-64,648,000 USD
Net income
-68,357,000 USD
Operating cash flow
-70,097,000 USD